Regorafenib

Generic Name
Regorafenib
Brand Names
Stivarga
Drug Type
Small Molecule
Chemical Formula
C21H15ClF4N4O3
CAS Number
755037-03-7
Unique Ingredient Identifier
24T2A1DOYB
Background

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...

Associated Conditions
Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-
Clinical Trials
Related News

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

First Posted Date
2022-01-18
Last Posted Date
2024-07-30
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
30
Registration Number
NCT05194293
Locations
🇺🇸

Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

First Posted Date
2021-12-16
Last Posted Date
2024-07-15
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
250
Registration Number
NCT05159245
Locations
🇫🇮

Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland

🇫🇮

Kuopio University Hospital, Kuopio, Finland

🇫🇮

Oulu University Hospital OYS Cancer Center, Oulu, Finland

and more 2 locations

Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

Phase 2
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: regorafenib
First Posted Date
2021-11-26
Last Posted Date
2023-04-26
Lead Sponsor
CHA University
Target Recruit Count
40
Registration Number
NCT05134532
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

First Posted Date
2021-11-22
Last Posted Date
2021-12-06
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
130
Registration Number
NCT05130021
Locations
🇨🇳

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

First Posted Date
2021-11-09
Last Posted Date
2024-12-11
Lead Sponsor
Sarah K. Lynam MD
Target Recruit Count
31
Registration Number
NCT05113368
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

First Posted Date
2021-10-01
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
505
Registration Number
NCT05064059
Locations
🇨🇳

Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China

🇨🇳

Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning, Guangxi, China

🇨🇳

Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan, Hubei, China

and more 149 locations

Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis

First Posted Date
2021-09-27
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05057052
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

First Posted Date
2021-09-17
Last Posted Date
2023-03-29
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
20
Registration Number
NCT05048017
Locations
🇨🇳

Hai-Tao Zhao, Beijing, Beijing, China

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

First Posted Date
2021-08-27
Last Posted Date
2021-09-02
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
60
Registration Number
NCT05025592

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

First Posted Date
2021-08-02
Last Posted Date
2022-09-01
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
1
Registration Number
NCT04985136
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy